DermaPure

ApprovedBiologic

CColorado Pelvic Floor Consultants

DermaPure is one of 14 biologic programs targeting Pelvic Organ Prolapse. It is currently in Approved.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Pelvic Organ ProlapseActive, not recruiting

Pelvic Organ ProlapseApproved

Active, not recruiting

Competition

Competitive Landscape

16 competitors in Pelvic Organ Prolapse

#DrugCompanyPhaseTrials

Decadron

AAspen Global Incorporated

Cyklokapron

Neurontin

VViatris Specialty LLC

Activella

1 5

One-Alpha

Roche

Phase 3

1 6

Conjugated Estrogen

Pfizer

Approved

1 7

IV Acetaminophen

AAFT Pharmaceuticals, Ltd.

Approved

1 8

Estriol

IITF Research Pharma, S.L.U.

Approved

1 9

Detrol La

PPfizer's Upjohn has merged with Mylan to form Viatris Inc.

Phase 3

1 10

Promestriene

UUniversity of Sao Paulo General Hospital

Approved

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Pelvic Organ Prolapse1 trial

Surgical Intervention With DermaPure vs Native Tissue in Pelvic Organ Prolapse

Unknown status·CColorado Pelvic Floor Consultants·Phase 4·NCT03939715·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for DermaPure. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — DermaPure compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for DermaPure. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Colorado Pelvic Floor Consultants company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Approved[1]
Company: CColorado Pelvic Floor Consultants

DermaPure

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Pelvic Organ Prolapse1 trial

References

Drug Info

Quick Facts

Related News